Heyman Richard A.
SEC-identified person · CIK 1584759 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Imara Inc. IMRA | Director | filed 2023 - 2026 |
| Oric Pharmaceuticals, Inc. ORIC | Director | filed 2020 - 2026 |
| PMV Pharmaceuticals, Inc. PMVP | Director | filed 2020 - 2025 |
| Rayzebio, Inc. RYZB | Director | filed 2023 - 2024 |
| Metacrine, Inc. MTCR | Director | filed 2020 - 2022 |
| Gritstone bio, Inc. GRTS | Director | filed 2018 - 2022 |
| Yumanity Therapeutics, INC. YMTX | Director | filed 2020 - 2021 |
| Tango Therapeutics, Inc. TNGX | Director | filed 2020 - 2020 |
| Receptos, Inc. RCPT | Director | filed 2014 - 2015 |
| Vivosim Labs, INC. VIVS | Director | filed 2013 - 2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.